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EXECUTIVE SUMMARY 
 
Data Report on Cancer in Children and Adolescents in Massachusetts, 2000-2009 presents 
cancer incidence and mortality data from 2000 through 2009 for children and adolescents (birth 
to 19 years) who were residents of Massachusetts at the time of diagnosis. This report updates 
the Massachusetts Cancer Registry’s report, Childhood Cancer in Massachusetts 1990-1999, 
and provides information about the most common types of childhood cancer including 
differences by age, gender, and race/ethnicity.  Time trends from 2000 to 2009 are analyzed 
and cancer- related deaths for both childhood (0-14) and adolescence (15-19) are detailed.   
 
The decreased mortality rate of childhood/adolescent cancer has been one of the major success 
stories of medicine in the last 20 years. Although the overall death rate for these cancers did not 
decline significantly from 2000 to 2009, it did decrease significantly from 1990 to 2009 (see 
graph below for yearly death rates and the average annual change in death rate as indicated by 
the straight line). Consistent with national statistics, leukemia incidence rates increased 
significantly from 2000 to 2009. This increase was due in part to an increase in the rate of a 
specific subtype known as acute lymphocytic leukemia.  As with overall childhood/adolescent 
mortality trend data in Massachusetts, the 20 year mortality trend for leukemia decreased 
significantly. 
 
Public health and reports such as this one provide baseline tracking of the new cases 
(incidence) and mortality of diseases. Cancer is one of the top three reasons for childhood 
deaths.  While progress is being made, continued surveillance over time for research and 
vigilance is needed to measure successes, and where there is opportunity to make an impact.   
 
 
 
Data Highlights from the Report 
 
 
 From 2000 through 2009, 3,001 invasive cancer cases were diagnosed among 
Massachusetts children and adolescents.  The age-adjusted incidence rate of childhood 
invasive cancers declined non-significantly from 2000 to 2009 for both genders.  
 
 Males represented 53.4% of all childhood/adolescent cancers and females 46.6%.  The 
three most common cancers among males in this age group were leukemia (23.6%), 
cancers of the brain and central nervous system (CNS) (19.0%), and lymphoma 
(18.7%).  Among females, they were leukemia (23.3%), cancers of the brain and CNS 
(18.3%), and malignant epithelial neoplasms (15.2%), the most common of which were 
thyroid cancer (8.0%) and melanoma (4.4%).  
 
 Malignant epithelial neoplasm rates increased significantly from 2000 to 2009. Much of 
this increase can be attributed to a significant increase in thyroid cancer, likely due to 
better detection of smaller tumors (see Data Report: Thyroid Cancer in Massachusetts 
www.mass.gov/dph/mcr ).  Significantly more females than males were diagnosed with 
thyroid cancer and the majority of cases occurred in the 15-19 age group. 
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 From 2000-2009, cancer was ranked the 6th most common cause of death for children 
ages 0-4 (75 deaths, 1.7%), the 2
nd
 most common for children ages 5-9 (86 deaths, 
23.2%), the 2
nd
 most common for children ages 10-14 (94 deaths, 18.8%), and the 2
nd
 
most common for adolescents ages 15-19 (131 deaths, 7.5%).  Of the 386 cancer deaths 
among children and adolescents, the three most common were leukemia (29.4%), CNS 
cancer (23.2%), and adrenal gland cancer (9.8%). 
 
 
Childhood and Adolescent Cancer Age Adjusted Death Rates, 1990-2009: 
 
 Source: Massachusetts Registry of Vital Records and Statistics and National Center for Health Statistics. * Rates are 
age-adjusted to the US standard 2000 population for ages 0-19. 
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METHODS 
 
Sources of Incidence and Mortality Data: 
 
The Massachusetts Cancer Registry (MCR): All Massachusetts incidence data are provided 
by the MCR, which is part of the Massachusetts Department of Public Health (MDPH).  The 
MCR is a population-based registry that began collecting reports of newly-diagnosed cancer 
cases in 1982.  The MCR collects reports of these cancer cases from health care facilities and 
practitioners throughout Massachusetts. Facilities currently reporting to the MCR in 2012 
include 65 Massachusetts  acute care hospitals, 6 radiation centers, 3 endoscopy centers, 4 
surgical centers, 19 independent laboratories, 2 medical practice associations, 4 
radiation/oncology centers and approximately 500 private practice physicians. Additionally, the 
MCR has reciprocal reporting agreements with 25 states to obtain data on Massachusetts 
residents diagnosed out of state.  Currently the MCR collects information on in situ (except 
cervix) and invasive cancers and benign tumors of the brain and associated tissues. The MCR 
does not collect information on basal and squamous cell carcinomas of the skin.  The MCR also 
collects information from reporting hospitals on cases diagnosed and treated in physician 
offices when this information is available. Not all hospitals report these physician office cases, 
however, some hospitals report such cases as if the patients had been diagnosed and treated by 
the hospital directly. Collection of these data makes the MCR’s overall case ascertainment 
more complete. Some cancer types that may be reported to the MCR in this manner are 
melanoma, prostate, colon/rectum, and oral cancers.  The MCR also identified and included 
cancers noted on death certificates that were not previously reported to the MCR. 
 
To improve case completeness, this MCR report includes previously unreported cancer cases 
that have been discovered through death certificate clearance.  This process identifies cancers 
mentioned on death certificates that were not previously reported to the MCR.  In some 
instances, the MCR was able to obtain additional information on these cases through follow-up 
activities with hospitals, nursing homes and physicians’ offices.  In other instances, a cancer-
related cause of death recorded on a Massachusetts death certificate is the only source of 
information for a cancer case.  These “death certificate only” cancer diagnoses are, therefore, 
poorly documented, and have not been confirmed by review of complete clinical information.  
Such cases are included in this report, but they comprise less than 3% of all cancer cases for the 
years covered by this report.  
 
Each year, the North American Association of Central Cancer Registries (NAACCR) reviews 
cancer registry data for quality, completeness, and timeliness.  For diagnosis years 2000-2009, 
the MCR annual case count was estimated by NAACCR to be more than 95% complete each 
year.  The MCR achieved the gold standard for this certification element, in addition to six 
other quality and timeliness elements for each year during 2000-2009.   
 
Childhood cancers are classified differently from adult cancers.  Whereas adult cancers are 
coded first using the cancer origin or primary site and then by histology, childhood cancers are 
predominately classified according to histology or tissue type regardless of primary site.  The 
International Classification of Childhood Cancer, Third Edition (ICCC-3), based on the 
histology codes used in the International Classification of Diseases for Oncology, Third Edition 
(ICD-O-3), was developed to standardize the classification of childhood cancer cases.
1
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Case reports for 2000 were coded following the International Classification of Diseases for 
Oncology, Second Edition (ICD-O-2) and converted to International Classification of Diseases 
for Oncology, Third Edition (ICD-O-3); ICD-O-2 was converted to ICD-O-3 in 2001.  Cases 
reported from 2001 through 2009 were coded following the ICD-O-3 system.  All cases 
diagnosed in children and adolescents were then grouped into International Classification of 
Childhood Cancer, Third Edition (ICCC-3) categories.  The ICCC-3 system groups ICD-O-3 
histology and site codes into 12 categories.  Although the ICCC includes some tumors of 
benign or uncertain behavior in its classification of central nervous system and intracranial and 
intraspinal neoplasms, those tumors are not included in this report, which focuses on invasive 
Massachusetts cancers only.   
 
Surveillance, Epidemiology, and End Results (SEER):  National data on cancer incidence 
are from the National Cancer Institute’s SEER Program, an authoritative source on cancer 
incidence and survival in the United States that collects and publishes data from registries in 
selected areas.  The national cancer incidence data in this report include malignant cases from 
the 18 SEER areas (including Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San 
Francisco-Oakland, Seattle-Puget Sound, Utah, Los Angeles, San Jose-Monterey and Alaska, 
rural Georgia, greater California, Kentucky, Louisiana, New Jersey, and greater Georgia).  
SEER rates are presented per 100,000 persons and are age-adjusted to the 2000 United States 
standard population for ages 0-19 years.  Please note that cases diagnosed in Louisiana from 
July to December 2005 were excluded as a result of Hurricane Katrina.
2
 
 
Massachusetts Registry of Vital Records and Statistics (MVRS): Massachusetts death data 
were obtained from the MDPH’s Registry of Vital Records and Statistics, which has legal 
responsibility for collecting reports of deaths of Massachusetts residents.   
 
National Center for Health Statistics (NCHS):  National mortality data were obtained from 
the Centers for Disease Control’s National Center for Health Statistics, which collects national 
death data from individual state vital statistics registries. In contrast to national incidence data, 
mortality data include the entire United States. 
 
 
Statistical Terms: 
 
Age-Specific Rates – Age-specific rates were calculated by dividing the number of people in 
an age group who were diagnosed with cancer or died of cancer in a given time frame by the 
number of people in that same age group overall in that time frame. They are presented as rates 
per 100,000 residents and are cancer type and sex specific. 
 
Age-Adjusted Rates – For most other MCR publications that focus on a specific cancer or 
cancers in the general population, age adjustment is based on 18 age groups (0-4, 5-9, 10-14, 
15-19, etc. to 85+).  The percentage that each age group comprised of the total United States 
2000 population is multiplied by the age-specific rate for a cancer to obtain an adjusted rate.  
The age-adjusted rate for a specific cancer is derived by adding the 18 age group-specific rates 
into one age-adjusted rate.  Age adjustment controls for age differences in cancer incidence.  
For this report, age adjustment was based on the first four age groups (0-4, 5-9, 10-14, and 15-
19).  The population percentages of each of these four groups were derived from the US 2000 
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population.  From this derivation, age-adjusted cancer rates for 0-19 year olds were calculated 
in the same manner as the age adjustment for the 18 age groups. Age-adjusted rates can only be 
compared if they are adjusted to the same standard population. 
 
Joinpoint Regression Analysis of Cancer Trends – The annual percent change (APC) 
=100*(e
m
-1), where m is a slope of the linear regression line, which is an approximation of the 
function of the natural logarithm of the rates by the year of diagnosis.  The APC is a linear 
approximation; therefore, it may not give an accurate picture of long-term trend.  SEER 
provides software to calculate the number and location (in time) of points where trends change 
direction (joinpoints).
3
 At each joinpoint, the trend may change in different ways.  The 
joinpoint regression model describes the trend as a sequence of linear segments between 
corresponding joinpoints so that each segment has an associated APC positive trend, negative 
trend, or no trend. 
 
Proportion Comparisons – Proportions were compared for significance using the modified 
Wald Method on graph pad software http://graphpad.com/quickcalcs/confInterval1/   
Significance for rate comparisons was determined by comparing the 95% confidence intervals 
for two rates.  If the intervals overlapped, the difference between the rates was not considered 
to be statistically significant.  If, however, there was no overlap between the confidence 
intervals, then the difference in rates was considered to be statistically significant.  For the sake 
of brevity, all statistically significant differences in this report will be referred to as being 
significantly different and not statistically significantly different. 
 
Survival - The calculation of minimum five-year survival time was limited to Massachusetts 
and US SEER cases diagnosed from 2000 to 2004 since mortality data were available only 
through 2009.  Survival analyses were done only for those cancers with 20 or more incident 
cases from 2000 to 2004.  Cumulative five-year survival times were calculated using the life 
table or actuarial method whereby only cancer specific causes of death were used as an 
endpoint and all other causes of death were censored, or excluded from analyses.  Survival 
rates were computed for each of the 5-year periods and then multiplied to obtain a cumulative 
survival rate.  For example, if 96.8% survived the first year, 94.6% the second year, 93.2% the 
third year, 96.3% the fourth year, and 98.7% the fifth year, the five-year cumulative survival 
would be .968 x .946 x .932 x .963 x .987, or 81.1%.  The SEER survival data presented are 
also cause-specific and computed by the actuarial method.
4
 
 
Population Estimates: 
 
All of the population estimates used in this report were produced by the NCHS in collaboration 
with the Census Bureau‘s Population Estimation Program.  The NCHS reallocates the multiple 
race categories from the Census Bureau population estimates file to create four mutually 
exclusive race categories that are consistent with the race categories used to collect cancer 
incidence and cancer mortality data for the years 2000-2009.  
 
Race/Ethnicity:  
 
The race/ethnicity categories presented in this report are mutually exclusive.  Cases and deaths 
are only included in one race/ethnicity category.  The race/ethnicity tables include the 
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categories white, non-Hispanic; black, non-Hispanic; Asian, non-Hispanic; and Hispanic.  The 
total population in Massachusetts also includes unknown races/ethnicities and Native 
Americans.  As a result, the number of cases for the total population is not the sum of cases by 
race/ethnicity.   
 
 
Data Limitations: 
 
When interpreting the cancer data, it is important to consider certain limitations which include: 
 
 Under-reporting in areas close to neighboring states: Although the MCR has reciprocal 
reporting agreements with 25 states, including all New England states, there may still be 
some Massachusetts residents who were diagnosed out of state and not reported to the MCR 
 Potentially misleading trends: Apparent increases or decreases in cancer incidence over 
time may reflect changes in diagnostic methods or case reporting rather than true changes in 
cancer occurrence.   
 Small numbers of cases: Many of the calculations in this report involved small numbers of 
cases.  As a result, differences in rates may be due to chance, and the data should be 
interpreted with caution. 
 Misclassification and/or under-reporting of racial/ethnic data: Data on race/ethnicity are 
based on information existing in the medical record for cancer cases and information on the 
death certificate for cancer deaths.  Errors in these source documents may lead to incorrect 
classification of race/ethnicity.   
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CHILDHOOD AND ADOLESCENT CANCER INCIDENCE AND MORTALITY 
 
Incidence: 
 
From 2000-2009, there were 3,001 invasive cancer cases diagnosed among Massachusetts 
children and adolescents through the age of 19.  For both males and females, the age-adjusted 
incidence of all cancers combined among children and adolescents did not change significantly 
from 2000-2009, with annual percent changes (APC) of 1.0% and 0.8%, respectively.  
Nationally, US SEER incidence rates for male and female children and adolescents also 
showed non-statistically significant increases (APC of 0.5% for both sexes) (Figure 1). 
 
 
Source: Massachusetts Cancer Registry and SEER 18 Registries. *Rates are age-adjusted to the US standard 2000 
population for ages 0-19. 
 
Massachusetts males represented 53.4% of the cancer cases and females 46.6% (Figures 2 and 
3).  The three most common cancers diagnosed among male Massachusetts children and 
adolescents from 2000 to 2009, accounting for 61.3% of all cases, were leukemia, cancers of 
the brain and central nervous system, and lymphoma.  The three most common of these cancers 
for females, accounting for 56.8% of all cases, were leukemia, cancers of the brain and central 
nervous system (CNS) and malignant epithelial neoplasms.  The most common epithelial 
neoplasms were thyroid cancer (8.0% of all cases) and melanoma (4.4% of all cases).  No other 
grouping accounted for more than 10% of childhood and adolescent cancer in either sex.   
 
Nationally, males represented 54.3% of childhood and adolescent cancers diagnosed from 2000 
to 2009 and females represented 45.7%.  The three most common of these cancers for males 
were leukemia, lymphoma, and CNS cancer, representing 60.8% of all cancers.  Nationally, the 
three most common of these cancers for female children and adolescents were leukemia, brain 
and CNS cancer, and malignant epithelial neoplasms, representing 57.1% of all cancers.  
Lymphoma, representing 12.7% of female cancers, ranked fourth. 
0
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Figure 1: Age-Adjusted Incidence Rate for All Cancers* Among Children and 
Adolescents  By Sex, 2000-2009 
Male MA Male SEER Female MA Female SEER
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Source: Massachusetts Cancer Registry 
 
 
Source: Massachusetts Cancer Registry 
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Figure 2: Childhood/Adolescent Male Cancer Cases by Type,                 MA, 
2000-2009 (N=1603) 
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Figure 3: Childhood/Adolescent Female Cancer Cases by Type,             MA, 2000-
2009 (N=1398) 
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Mortality: 
 
From 2000-2009 in Massachusetts, cancer was ranked the 6
th
 most common cause of death for 
children ages 0-4 (75 deaths, 1.7%), the 2
nd
 most common for children ages 5-9 (86 deaths, 
23.2%), the 2
nd
 most common for children ages 10-14 (94 deaths, 18.8%), and the 2
nd
 most 
common for adolescents ages 15-19 (131 deaths, 7.5%).  During this time period, there were 
386 deaths with cancer as an underlying cause of death among children and adolescents.  Since 
the number of deaths was small, Massachusetts death data were not broken down by sex.  The 
national death data were not broken down by sex to be consistent with Massachusetts data.  The 
death rate has been decreasing with an APC of -2.2% for Massachusetts and -2.0% for the 
United States.  The trend, however, was only statistically significant for national statistics.  The 
20-year trend in Massachusetts from 1990 to 2009 (not pictured), however, indicated a 
statistically significant decrease (APC=-1.8%) in cancer deaths among children and 
adolescents. 
 
 
Source: Massachusetts Registry of Vital Records and Statistics and National Center for Health Statistics. * Rates 
are age-adjusted to the US standard 2000 population for ages 0-19. 
 
Leukemia accounted for 27.8% of cancer deaths among Massachusetts children and adolescents 
of both sexes from 2000-2009,  the leading cause of death from cancer for this group. Central 
nervous system cancer was second and accounted for 23.7% of deaths.  Cancers of the adrenal 
gland (related to neuroblastoma), bone, and soft tissue comprise the top five causes of death 
from cancer, accounting for 9.8%, 9.8%, and 8.8% of deaths, respectively (Figure 5). 
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Figure 4: Cancer Age-Adjusted Death Rates Among Children and 
Adolscents, MA and US, 2000-2009 
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Source: Massachusetts Registry of Vital Records and Statistics.  
 
CHILDHOOD AND ADOLESCENT CANCER INCIDENCE BY AGE GROUP: 
 
When analyzing age-specific rates, children under the age of 5 and adolescents ages 15 to 19 
had higher cancer rates than those ages 5 to 14.  The age group 15-19 was the only age group 
displaying a  significantly increasing trend with an APC of 2.1% (Figure 6). 
 
Source: Massachusetts Cancer Registry.  
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Figure 5: Male and Female Childhood/Adolescent Cancer Deaths by Type, 
MA, 2000-2009 (N=386) 
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Figure 6: Cancer Age-Specific Incidence* Among Children and 
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Table 1: Age-specific incidence rates and 95% confidence intervals of leading cancers among 
children and adolescents by age group and sex, Massachusetts, 2000-2009 
       
Age 00-04 years    Age 05-09 years   
Rank Males Females  Rank Males Females 
 All Cancers     
23.1 (20.9, 25.2) 
All Cancers     
23.7 (21.6, 26.0)  
 All Cancers   
13.6 (12.0, 15.2) 
All Cancers     
10.9 (9.5, 12.4) 
1 Leukemia          
8.0 (6.7, 9.2) 
Leukemia        
9.0 (7.6, 10.3)  
1 
Central Nervous 
System               
4.6 (3.7, 5.5) 
Central Nervous 
System               
3.5 (2.7, 4.4) 
2 
Central Nervous 
System                  
4.6 (3.6, 5.5) 
Central Nervous 
System                  
 4.7 (3.7, 5.7)  
2 Leukemia        
3.6 (2.7, 4.4) 
  Leukemia       
3.0 (2.2, 3.7) 
3 
Peripheral 
Nervous System                   
4.3 (3.4, 5.2) 
Peripheral 
Nervous System           
3.8 (2.9, 4.7)  
3 Lymphoma     
2.4 (1.7, 3.0) 
Soft Tissue 
Sarcomas         
1.0 (0.5, 1.4) 
4 Renal Tumors                   
1.8 (1.2, 2.3) 
Renal Tumor               
 1.7 (1.1, 2.3)  
4 
Soft tissue 
sarcoma           
0.9 (0.5, 1.3) 
 Renal Tumor     
0.9 (0.5, 1.3) 
5 
Soft Tissue 
Sarcoma            
1.3 (0.8, 1.9) 
Retinoblastoma  
1.3 (0.7, 1.8)  
5 Renal Tumor              
0.6 (0.3, 0.9) 
Lymphoma     
0.7 (0.3, 1.1)                 
       
Age 10-14 years    Age 15-19 years   
Rank Males Females  Rank Males Females 
 All Cancers     
14.4 (12.8, 16.0) 
All Cancers     
12.4 (10.9, 13.9)  
 All Cancers     
25.2 (23.1, 27.2) 
All Cancers     
22.4 (20.4, 24.4) 
1 Lymphoma     
4.2 (3.3, 5.0) 
Central Nervous 
System                 
2.5 (1.8, 3.2)  
1 Lymphoma     
6.6 (5.5, 7.7) 
Epithelial Tumor            
7.8 (6.6, 9.0) 
2 Leukemia        
3.1 (2.4, 3.8) 
Lymphoma    
 2.5 (1.8, 3.2)  
2 Germ cell        
4.0 (3.2, 4.9) 
Lymphoma      
5.8 (4.8, 6.8) 
3 
Central Nervous 
System                
2.8 (2.1, 3.5)       
Leukemia        
 2.3 ( 1.7, 3.0)  
3 Epithelial Tumor        
4.0 (3.2, 4.9)       
Leukemia         
2.3 (1.7, 2.9) 
4 Bone               
1.5 (1.0, 2.0) 
Epithelial Tumor         
1.9 (1.3, 2.5)  
4 Leukemia        
3.6 (2.8, 4.4) 
Central Nervous 
System                 
2.2 (1.5, 2.8) 
5 Epithelial Tumor         
1.2 (0.8, 1.7) 
Bone               
 1.1 (0.6, 1.5)  
5 
Central Nervous 
System            
2.8 (2.1, 3.5)           
Soft Tissue 
Sarcoma           
1.7 (1.2, 2.3) 
Source: Massachusetts Cancer Registry.  
 
 
  13 
The age-specific incidence rate of childhood cancer was highest among Massachusetts males  
15-19 years old and for females 0-4 years old (Table 1).  The rates for both males and females 
in these two groups were both statistically significantly elevated when compared to males and 
females of the other two groups (5-9 and 10-14).  The most common cancers among children 
and adolescents varied by age group and sex. Leukemia ranked number one among 0-4 year 
olds for both males and females, with significantly higher rates than any other cancer in this 
age group.  Central nervous system tumors ranked number one among 5-9 years old for both 
males and females.  Lymphomas ranked number one for males and central nervous system 
tumors rank number one for females in the 10-14 years old group.  Lymphomas ranked number 
one for males and malignant epithelial neoplasms ranked number one for females in the 15-19 
years old group who had a significantly higher rate of epithelial tumors compared to males.  
The rate of all cancers among females in Massachusetts aged 0-4 was significantly elevated 
compared to the SEER rate (23.7, CI=21.6-26.0 vs. 19.5, CI=19.0-20.1).  Additionally, the 
lymphoma rate among males in Massachusetts aged 10-14 was significantly elevated compared 
to the national rate (4.2, CI=3.3-5.0 vs. 3.0, CI=2.8-3.2).  Otherwise, there were no significant 
differences between Massachusetts and SEER rates.  
 
CHILDHOOD AND ADOLESCENT CANCER INCIDENCE BY RACE: 
The following five figures compare childhood and adolescent cancer incidence trends by race 
and ethnicity.  The first figure (Figure 7) compares the incidence trends from 2000-2009 for the 
four major racial/ethnic groups in Massachusetts.  The rates for white, non-Hispanics (NH) and 
Asian, NHs increased non-significantly with APCs of 1.3% and 7.4%, respectively.  The 
incidence rate for black, NHs decreased significantly with an APC of -11% from 2000-2004 
and then increased significantly with an APC of 9.1% from 2005-2009.  The incidence rate for 
Hispanics increased significantly with an APC of 4.6% from 2000-2009.  It should be noted 
that, with the exception of the white, NH case numbers (n=2387), the other numbers were small 
and had less stable rates (black, NH=175, Asian, NH=108, Hispanic=272).  For example, when 
there are 6 cases in a given year, an increase of even 2 or 3 cases the following year can 
possibly indicate a trend when there isn’t one, especially if the number falls back to 5 the 
following year. 
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Source: Massachusetts Cancer Registry. * Rates are age-adjusted to the US standard 2000 population for ages 0-19 
 
Nationally, the incidence rates for white, NHs, increased non-significantly with an APC of 
0.1% (Figure 8). For black, NHs the trend increased with a significant APC of 2.0% (Figure 9); 
for Asian, NHs the trend increased non-significantly with an APC of 2.0% despite some annual 
fluctuations (Figure 10); and for Hispanics the trend increased significantly with an APC of 
1.3% (Figure 11).  As opposed to the state trends for black, NHs, Asian, NHs, and Hispanics, 
the national numbers were much larger and as a result, the trends are less subject to small 
fluctuations in annual case numbers.
 
Sources: Massachusetts Cancer Registry and SEER 18 Registries. * Rates are age-adjusted to the US standard 
2000 population for ages 0-19. 
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Figure 7: Age-Adjusted Incidence Rate for All Cancers* Among Children and 
Adolescents in MA by Race/Ethnicity, 2000-2009 
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Figure 8: Age-Adjusted Incidence Rate for All Cancers* Among White, non-
Hispanic Children and Adolescents, MA and US SEER, 2000-2009 
MA SEER
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Sources: Massachusetts Cancer Registry and SEER 18 Registries. * Rates are age-adjusted to the US standard 
2000 population for ages 0-19. 
 
 
Sources: Massachusetts Cancer Registry and SEER 18 Registries. * Rates are age-adjusted to the US standard 
2000 population for ages 0-19 
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Figure 9: Age-Adjusted Incidence Rate for All Cancers* Among Black, non-
Hispanic Children and Adolescents, MA and US SEER, 2000-2009 
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Figure 10: Age-Adjusted Incidence Rate for All Cancers* Among Asian, non-
Hispanic Children and Adolescents, MA and US SEER, 2000-2009 
MA SEER
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Sources: Massachusetts Cancer Registry and SEER 18 Registries. * Rates are age-adjusted to the US standard 
2000 population for ages 0-19 
 
 
 
From 2000-2009, Massachusetts white, NH children and adolescents had a significantly higher 
age-adjusted incidence rate for all cancers combined and CNS cancers compared to the three 
other racial/ethnic groups (Table 2).  There were no significant differences between black, 
NHs, Asian, NHs, and Hispanics. Of the five leading cancers for each racial/ethnic group, three 
were the same (leukemia, CNS and Lymphoma) but differed in the ranking.  When compared 
to the national SEER rates, the rate of all cancers among Hispanics was significantly lower 
(14.0, CI=12.4-15.7 vs. 16.5, CI=16.1-16.8).  Otherwise, there were no significant differences 
in rates between Massachusetts and the nation. 
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Figure 11: Age-Adjusted Incidence Rate for All Cancers* Among Hispanic 
Children and Adolescents, MA and US SEER, 2000-2009 
MA SEER
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Table 2: Age-Adjusted Incidence rates and 95% Confidence Intervals of the top five 
cancers among children and adolescents by race/ethnicity, Massachusetts, 2000-2009 
rank White, NH Black, NH Asian, NH Hispanic 
 All Cancers     
19.3 (18.5, 20.1) 
All Cancers     
13.2 (11.3, 15.2) 
All Cancers  
12.4 (10.1, 14.7) 
All Cancers        
14.0 (12.4, 15.7) 
1 Leukemia          
4.6 (4.2, 5.0) 
Lymphoma        
2.6 (1.8, 3.5) 
Leukemia       
3.5 (2.3, 4.8) 
Leukemia              
4.1 (3.2, 5.0) 
2 
Brain/Central 
Nervous System              
3.8 (3.5, 4.2) 
Leukemia          
2.5 (1.6, 3.3) 
Lymphoma    
2.2 (1.2, 3.3) 
Brain/Central 
Nervous System                 
2.3 (1.7, 3.0) 
3 Lymphoma       
3.1 (2.8, 3.4) 
Central Nervous 
System              
1.8 (1.0, 2.5) 
Central Nervous 
System           
2.1 (1.2, 3.3) 
Lymphoma           
2.3 (1.6, 3.0) 
4 Epithelial Tumors  
2.0 (1.8, 2.3) 
Soft Tissue 
Sarcoma            
1.7 (1.0, 2.4) 
Soft Tissue 
Sarcoma         
1.0 (0.3, 1.6) 
Epithelial Tumors  
1.4 (0.8, 1.9) 
5 
Peripheral 
Nervous System                  
1.4 (1.2, 1.6) 
Renal Tumors   
0.9 (0.4, 1.4) 
Germ Cell 
Tumors          
0.8 (0.2, 1.4) 
Soft Tissue Sarcoma  
1.1 (0.6, 1.6) 
Source: Massachusetts Cancer Registry. * Rates are age-adjusted to the US standard 2000 population for ages 0-
19. 
 
SPECIFIC TYPES OF CHILDHOOD AND ADOLESCENT CANCERS: 
 
LEUKEMIA 
 
Leukemia is a general term that includes different cancers that occur in the bone marrow, which 
is responsible for supplying blood cells.  Any cell in the bone marrow can transform into a 
leukemia cell which can reproduce quickly and not die when it should.  The cells build up in 
the bone marrow and eventually enter the bloodstream.
5
 From 2000-2009, the 705 leukemia 
cases accounted for 23.5% of Massachusetts childhood and adolescent cancer cases compared 
with 26.7% of US SEER cases.  Figure 12 shows the trends in total leukemia incidence by age 
group from 2000-2009.  There was a significant increase in the incidence trend for childhood 
and adolescent leukemia in MA (APC=2.3%) but not in the US (APC=1.0%).   
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Figure 12: Age-Adjusted Leukemia Incidence Rates* Among Children and 
Adolescents, MA and US SEER, 2000-2009
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Source: Massachusetts Cancer Registry and SEER 18 Registries. * Rates are age-adjusted to the US standard 2000 
population for ages 0-19. 
 
Trends in leukemia incidence were compared between white, NHs and Hispanics.  These were 
the only two groups with enough cases to perform any meaningful analyses (a minimum of 5 
cases/year).  Since there were fewer than 5 cases among Hispanics in 2000, the trends were 
analyzed from 2001 to 2009.  While the incidence rates increased for both white, NHs and 
Hispanics (APCs of 1.3% and 2.9%, respectively), neither trend was significant.  (Figure 13) 
 
 
 
Source: Massachusetts Cancer Registry.* Rates are age-adjusted to the US standard 2000 population for ages 0-19. 
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Figure 13: Age-Adjusted Leukemia Incidence Rates* Among Children and 
Adolescents, White, NH and Hispanic MA , 2000-2009 
White, NH Hispanic
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There are five subgroups of leukemia (acute lymphoid leukemia, acute myeloid leukemia, 
chronic myeloproliferative leukemia, myelodysplastic syndrome, and unspecified leukemia). 
 
Acute lymphoid leukemia (ALL) is an acute (fast growing) leukemia that starts in the 
lymphoid cells of the bone marrow.
5
 Nationally, it accounted for 75.9% of all childhood and 
adolescent leukemias diagnosed from 2000-2009 while statewide it accounted for 77.7% 
(n=548) of leukemia cases. A significantly larger percentage of ALL cases were male 
compared to female (56.4% vs. 43.6%).  ALL was more likely to be diagnosed in the younger 
age groups with 72.5% of cases diagnosed before the age of 10 and 51.3% before the age of 5.  
There were statistically significant increases in the incidence trends for ALL in both 
Massachusetts and the US (APC=3.2 and 1.2, respectively) (Figure 14).   
 
 
Sources: Massachusetts Cancer Registry and SEER 18 Registries. * Rates are age-adjusted to the US standard 
2000 population for ages 0-19. 
 
Acute myeloid leukemia (AML) starts in myeloid cells that form white cells (other than 
lymphocytes), red blood cells, or platelets.
5
  It accounted for 18.3 % of US childhood and 
adolescent leukemia cases and 16.3% (n=115) of 2000-2009 Massachusetts cases of which 
44.4% were male and 55.7% female, no significant difference.  Of the Massachusetts cases, 
29.6% were diagnosed before the age of five and 61.8% were diagnosed between 10 and 19 
years.  In Massachusetts, the incidence trend for AML decreased non-significantly with an 
APC of 1.2% while nationally the trend remained stable with an APC of 0% (Figure 15). 
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Figure 14: Age-Adjusted Acute Lymphoid Leukemia (ALL) Incidence Rates* 
Among Children and Adolescents , MA and US SEER, 2000-2009 
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Sources: Massachusetts Cancer Registry and SEER 18 Registries. * Rates are age-adjusted to the US standard 
2000 population for ages 0-19. 
 
Chronic myeloproliferative leukemia (CML) is a chronic (slow growing) form of leukemia 
that occurs more often among older adults and is rare in children
5
. It accounted for 2.5% of US 
childhood and adolescent leukemia cases and 3.8% of Massachusetts cases (51.9% male and 
48.2% female, no significant difference).  Of the Massachusetts cases, 51.9% were diagnosed 
after the age of 14.  Since there were only 27 cases diagnosed in Massachusetts over the ten 
year period, it was not possible to meaningfully compare racial/ethnic groups or examine time 
trends. 
 
Myelodysplastic syndrome (MDS), also more frequent in adults and rare in children, is a bone 
marrow disorder sometimes referred to as ‘preleukemia’ due to its tendency to transform into 
acute myeloid leukemia.
6
 There were seven cases diagnosed over the ten year period, which 
was 1% of all Massachusetts childhood and adolescent leukemia cases similar to 0.8% of US 
SEER cases.  Of the Massachusetts cases, 71.4% were diagnosed before the age of five. 
 
Unspecified leukemias are cases reported without a type specified and accounted for 1.1% of 
Massachusetts leukemia cases (n=7) and 2.5% of US cases.  Of these cases, 87.5% were 
diagnosed before the age of five. 
 
Leukemia Mortality and Survival: 
 
There were 107 leukemia-related deaths among Massachusetts children and adolescents from 
2000 to 2009. The annual age-adjusted mortality rate for all leukemia cases aged 0-19 at the 
time of death was compared with US rates (Figure 16).  The Massachusetts trend decreased 
non-significantly (-0.2% APC) while the US trend decreased significantly (-2.6% APC).  The 
20-year trend in Massachusetts from 1990 to 2009 (not pictured), however, indicated a 
significant decrease (-3.1% APC) in leukemia deaths among children and adolescents. 
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Figure 15: Age-Adjusted Acute Myeloid Leukemia (AML) Incidence Rates* 
Among Children and Adolescents , MA and US SEER, 2000-2009 
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Source: Massachusetts Registry of Vital Records and Statistics and the National Center for Health Statistics.          
* Rates are age-adjusted to the US standard 2000 population for ages 0-19. 
 
Leukemia cases diagnosed from 2000 to 2004 were analyzed to determine the cumulative five 
year cause-specific survival in Massachusetts compared with US SEER survival.    
 
Childhood Cancer MA 5-Year 
Survival 
US SEER 5-Year 
Survival 
Acute Myeloid Leukemia (n=55) 72.8% 61.0% 
Acute Lymphoid Leukemia (n=246) 89.3% 86.0% 
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Figure 16: Age-Adjusted Leukemia Mortality Rate* Among Children and 
Adolescents, MA and US SEER, 2000-2009 
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LYMPHOMAS  
 
Lymphomas are cancers that develop in cells called lymphocytes, which are located in the 
lymph nodes and lymphoid tissues (such as the spleen and bone marrow) and are used in the 
fight against infections and disease.
7
  From 2000-2009, lymphoma accounted for 16.6% of MA 
childhood and adolescent cases (n=499) and 14.4% of US cases.  Figure 17 compares incidence 
trends for all lymphomas from 2000 to 2009 in Massachusetts and the US.  Neither the 
incidence trend in Massachusetts (APC= 2.6%) or in the US (US APC= 2.0%) was significant. 
 
Figure 17: Age-Adjusted Lymphoma Incidence Rates Among Children and 
Adolescents,  MA and US SEER, 2000-2009
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Source: Massachusetts Cancer Registry and SEER 18 Registries. * Rates are age-adjusted to the US standard 2000 
population for ages 0-19. 
 
There are 5 subgroups of childhood lymphoma: Hodgkin lymphoma (HL), non-Hodgkin 
lymphoma (NHL), Burkitt lymphoma, miscellaneous lymphoreticular neoplasms, and 
unspecified lymphoma. 
 
Hodgkin lymphoma (HL) is a type of lymphoma that involves the Reed-Sternberg cells.  
Those lymphomas that don’t involve these cells are referred to as non-Hodgkin lymphoma.8 
Among children and adolescents diagnosed with lymphoma from 2000 to 2009, 49.7% of US 
lymphoma cases fell into the HL category compared with 50.5% (n=252) of Massachusetts 
cases.  Of the Massachusetts childhood and adolescent cases, 92.5% were diagnosed between 
the ages of 10 and 19, with 65.5% of those diagnosed from 15 to 19. Of the HL cases, 51.2% 
were male and 48.8% female, a non-significant difference.    Figure 18 compares incidence 
trends for all HL cancer from 2000 to 2009 in Massachusetts and the US SEER Registries.  
While the incidence trend in Massachusetts was not significant (APC= -1.1%), the national 
trend was (APC= 2.0%). 
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Source: Massachusetts Cancer Registry and SEER 18 Registries. * Rates are age-adjusted to the US standard 2000 
population for ages 0-19. 
 
Non-Hodgkin lymphoma, excluding Burkitt lymphoma (NHL) in children comprises three 
main types.  Lymphoblastic and large cell lymphomas are categorized separately from Burkitt 
according to the ICCC-3 classifications.
7
  Of the US SEER childhood and adolescent 
lymphoma cases diagnosed from 2000 to 2009, 35.4% fell into this category compared with 
36.5% (n=182) of Massachusetts cases.  A significantly larger percentage of Massachusetts 
NHL cases were male compared to female (67.0% vs. 33.0%).  Of the NHL cases, 77.5% were 
diagnosed after the age of 14.  While the increasing incidence trend in Massachusetts was 
statistically significant (APC= 6.0%), the national trend was not (US APC= 0.1%) (Figure 19).   
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Figure 18: Age-Adjusted Hodgkin Lymphoma (HL) Incidence Rates Among 
Children and Adolescents, MA and US SEER, 2000-2009 
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Sources: Massachusetts Cancer Registry and SEER 18 Registries. * Rates are age-adjusted to the US standard 
2000 population for ages 0-19. 
 
Burkitt lymphoma is a form of non-Hodgkin lymphoma that develops from B lymphocytes 
and is one of the fastest growing cancers known.  A child will typically develop a large tumor 
in his/her abdomen that can sometimes block the intestines.
7
  While 10.1% of US childhood 
and adolescent lymphoma cases fell into this category, 11.0% of MA cases did (n=55).  A 
significantly larger percentage of these cases were male compared to female (78.2% vs. 
21.8%).  Only 7.3% of the cases were diagnosed before the age of five and the remaining age 
groups had relatively equal percentages ranging from 29.1% to 32.7%.   
 
Lymphoreticular neoplasm, not otherwise specified accounted for 1.4% of US lymphoma 
cases and 1.8% of MA lymphoma cases (n=9). 
 
Lymphoma, not otherwise specified accounted for 1.3% of US lymphoma cases and less than 
1% of MA cases (n<5). 
 
Lymphoma Mortality and Survival: 
 
There were 17 lymphoma-related deaths among children and adolescents from 2000 to 2009. 
There were too few deaths to calculate age-specific morality and the numbers were evenly 
distributed across the years. 
 
Lymphoma cases diagnosed from 2000 to 2004 were analyzed to determine the five-year 
cause-specific cumulative survival compared to US SEER survival.   
 
Childhood Cancer MA 5-Year Survival US SEER 5-Year Survival 
Hodgkin Lymphoma (n=122) 97.6% 95.2% 
Non-Hodgkin Lymphoma (n=68) 82.2% 83.4% 
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Figure 19: Age-Adjusted Non-Hodgkin Lymphoma (NHL) Incidence Rates 
Among Children and Adolescents, MA and US SEER, 2000-2009 
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CENTRAL NERVOUS SYSTEM 
 
Central nervous system and miscellaneous intracranial and intraspinal neoplasms (CNS cancer) 
include tumors that arise from the brain, spinal cord, and other sites within the skull and spinal 
cord.   From 2000-2009, CNS cancer accounted for 18.8% of Massachusetts childhood and 
adolescent cancer cases (n=563) and 17.4% of US cases.  Figure 20 compares incidence trends 
for all CNS cancer from 2000 to 2009 in Massachusetts and the US.  Neither trend was 
statistically significant (Massachusetts APC= -0.2% and US APC= 0.2%). 
 
 
Sources: Massachusetts Cancer Registry and SEER 18 Registries. * Rates are age-adjusted to the US standard 
2000 population for ages 0-19. 
 
There are 5 types of childhood brain and central nervous system cancers: ependymomas and 
choroid plexus tumors, astrocytomas, embryonal tumors, other gliomas, and other intracranial 
tumors.
9
   
 
Ependymomas and choroid plexus tumors start in the ependymal cells that line the ventricles 
or central canal of the spinal cord.  They may spread along the cerebrospinal fluid (CSF) but do 
not spread outside the brain or spinal cord.  Unlike astrocytomas and oligodendrogliomas, they 
don’t usually grow into brain tissue.  Choroid plexus tumors are rare tumors that start in the 
choroid plexus within the ventricles of the brain.
9
  These tumors accounted for 9.1% of CNS 
childhood and adolescent cancers diagnosed in Massachusetts (n=51) and 8.7% diagnosed in 
the US.  There was no significant difference in the percentage of these cases that were male 
compared to female (56.9% vs. 43.1%). The numbers were too small for any trend analysis. 
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Figure 20: Age-Adjusted Central Nervous System Cancer Incidence Rates 
Among Children and Adolscents, MA and US SEER, 2000-2009 
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Astrocytomas can spread widely throughout and mingle with normal brain tissue.  There are 
three grades of astrocytomas: low grade – slow growing and the most common type in children, 
anaplastic – moderate growing, and gliobastoma – the highest grade and the fastest growing. 
Most of the tumors that develop within the brain begin in cells known as astrocytes, a type of 
glial cell.
9
  They accounted for 49.7% of CNS childhood and adolescent cancers diagnosed in 
Massachusetts (n=280) and 49.0% diagnosed in the US.    There was no significant difference 
in the percentage of astrocytoma cases that were male compared to female (53.6% vs. 46.4%) 
and no strongly predominant age group. Figure 21 compares incidence trends for malignant 
astrocytomas from 2000 to 2009 in Massachusetts and the US.  Neither trend was significant 
(Massachusetts APC= -1.9% and US APC= 0.3%).   
 
 
Sources: Massachusetts Cancer Registry and SEER 18 Registries. * Rates are age-adjusted to the US standard 
2000 population for ages 0-19. 
 
Embryonal tumors begin in embryonic (fetal) cells in the brain and spinal cord.  There are six 
types of embryonal tumors: medulloblastoma, pineal gland tumors, CNS primitive 
neuroectodermal tumors, medulloepithelioma, and ependymoblastoma.
9
  They accounted for 
19.7% of CNS childhood and adolescent cancers diagnosed in Massachusetts (n=111) and 
21.8% diagnosed in the US.  There was no significant difference in the percentage of 
embryonal tumor cases that were male compared to female (51.4% vs. 48.7%) and 39.6% of 
the cases were diagnosed before the age of 5 compared to 31.5% from age 10-19.  Figure 22 
compares incidence trends for malignant embryonal tumors from 2000 to 2009 in 
Massachusetts and the US.  Neither trend was significant (Massachusetts APC= -0.5% and US 
APC= -0.8%).   
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Figure 21: Age-Adjusted Astrocytoma Incidence Rates Among Children and 
Adolscents, MA and US SEER, 2000-2009 
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Sources: Massachusetts Cancer Registry and SEER 18 Registries. * Rates are age-adjusted to the US standard 
2000 population for ages 0-19. 
 
Other gliomas, representing other types of malignant gliomas, accounted for 16.7% of 
Massachusetts CNS childhood and adolescent cancers (n=94) and 17.6% of US CNS cancers 
diagnosed among 0-19 year olds from 2000-2009.  There was no significant difference in 
percentage of diagnoses between males and female cases (58.5% vs. 41.5%).  There also was 
no predominant age group diagnosed with this cancer. 
 
Other intracranial tumors, representing CNS cancers not otherwise categorized, accounted 
for 4.3% of CNS cancers in Massachusetts (n=24) and 2.9% in the US. 
 
CNS Mortality and Survival: 
 
In Massachusetts, there were 91 CNS-related deaths among children and adolescents from 2000 
to 2009. The annual age-adjusted mortality rate for all CNS cases aged 0-19 at the time of death 
in Massachusetts and the US were compared from 2000-2009 (Figure 23).  In the US, the 
deaths decreased with an APC of -1.6%, which was not statistically significant.  The 
Massachusetts APC increase of 0.4% also was not significant.  
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Rate  
per  
100,000 
Year of Diagnosis 
Figure 22: Age-Adjusted Malignant Embryonal Tumor Incidence Rates 
Among Children and Adolscents, MA and US SEER, 2000-2009 
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Source: Massachusetts Registry of Vital Records and Statistics and the National Center for Health Statistics.          
* Rates are age-adjusted to the US standard 2000 population for ages 0-19. 
 
CNS cases diagnosed from 2000 to 2004 were analyzed to determine the five-year cause-
specific cumulative survival compared to US SEER survival. 
 
Childhood Cancer MA 5-Year Survival US SEER 5-Year Survival 
Ependymomas (n=27) 81.4% 72.2% 
Astrocytomas (n=146) 90.3% 84.0% 
Embryonal Tumors (n=58) 74.0% 64.5% 
Other Gliomas (n=38) 55.2% 58.1% 
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Figure 23: Age-Adjusted CNS Cancer Mortality Rate* Among Children and 
Adolescents, MA and US, 2000-2009 
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TUMORS OF PERIPHERAL NERVOUS SYSTEM  
 
The peripheral nervous system (PNS) consists of the sensory neurons (which send stimulus 
signals to the central nervous system (CNS)) and motor neurons (which send out action signals 
from the CNS).   The peripheral nervous system is divided into the sensory-somatic nervous 
system (which controls scent, sight, hearing, taste, facial muscles, swallowing, etc.) and the 
autonomic nervous system (which controls the heart, lungs, exocrine glands, endocrine glands, 
and other internal organs, in particular the intestines in an involuntarily manner).
10
  The two 
types of peripheral nervous system cancers in children are neuroblastomas and other peripheral 
nervous system cancers.  Since 98.8% of the cases were neuroblastomas, this section will focus 
on that cancer.  From 2000-2009, neuroblastomas accounted for 6.4% of Massachusetts cases 
(n=193) and 4.5% of US SEER cases (and 98.0% of all US SEER PNS cancers). Figure 24 
shows age-adjusted incidence trends for neuroblastoma from 2000 to 2009 for Massachusetts 
and the US, neither of which was statistically significant (Massachusetts APC= -0.7% and US 
APC=0.1%).  The large drop and rise in the Massachusetts trend line is a reflection of the small 
number of annual cases (see Appendix III).  There was no significant difference in the 
percentage of neuroblastoma cases that were male compared to female (54.9% vs. 45.1%) and 
81.9% of these cases were diagnosed before the age of 5.  
 
 
Sources: Massachusetts Cancer Registry and SEER 18 Registries. * Rates are age-adjusted to the US standard 
2000 population for ages 0-19. 
 
Peripheral Nervous System Mortality and Survival: 
 
There were 25 PNS-related deaths among children and adolescents from 2000 to 2009.  
Of the Massachusetts cases diagnosed from 2000 to 2004 diagnosed with neuroblastoma, 
75.0% survived at least 5 years post diagnosis compared with 74.6% of US SEER cases.  Over 
90% of the Massachusetts deaths listed adrenal gland cancer as the underlying cause of death. 
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Figure 24: Age-Adjusted Neuroblastoma Incidence Rates Among Children 
and Adolescents, MA and US SEER, 2000-2009 
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 MALIGNANT EPITHELIAL TUMORS 
 
Carcinomas are cancers that develop from epithelial cells that form in the lining of organs; 
these represent many different types of cancer, including organs of the  respiratory 
passageways, most organs of the digestive system, kidney tubules, walls of blood vessels, 
ovaries, urinary tract, and others.
11
    Of the epithelial carcinomas, 96.6% were diagnosed after 
the age of 14.  From 2000-2009, these cancers accounted for 11.1% of Massachusetts cases 
(n=333) and 9.9% of US SEER cases.   Figure 25 compares age-adjusted incidence trends from 
2000 to 2009 for Massachusetts (APC=3.7%, a statistically significant increase) and the US 
(APC=1.0%, a non-significant increase). 
 
 
Sources: Massachusetts Cancer Registry and SEER 18 Registries. * Rates are age-adjusted to the US standard 
2000 population for ages 0-19. 
 
There are six types of epithelial tumors usually seen among children and adolescents: 
adenocortical carcinomas, thyroid cancer, nasopharyngeal carcinoma, melanoma, other skin 
cancer, and other/unspecified carcinoma. 
 
Adrenocortical carcinoma is a very rare pediatric tumor that arises from the adrenal gland.  
This cancer represented 1.2% of malignant epithelial tumors diagnosed in the US and less than 
0.5% diagnosed in Massachusetts from 2000-2009 (n < 5). 
 
Thyroid cancer is a carcinoma that develops in the thyroid gland.  There were 146 cases 
diagnosed from 2000-2009, representing 43.8% of Massachusetts epithelial tumors, compared 
with 36.9% of US cases.  The incidence rates increased significantly in Massachusetts 
(APC=8.0%) and significantly in the US (APC=4.5%) (Figure 26).  This increase is mirrored in 
the adult population as well, with significant increases in incidence for both males and female 
in Massachusetts and the US.
12
  Significantly more thyroid cases were female compared to 
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Figure 25: Age-Adjusted Malignant Epithelial Tumor Rates Among Children 
and Adolescents, MA and US SEER, 2000-2009 
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male (76.7% vs. 23.3%).  The majority of thyroid cases occurred in the 15-19 age-group 
(80.8%) followed by the 10-14 age-group (16.4%). 
 
 
Sources: Massachusetts Cancer Registry and SEER 18 Registries. * Rates are age-adjusted to the US standard 
2000 population for ages 0-19. 
 
Nasopharyngeal carcinoma is a carcinoma that affects the nose and pharynx and is also 
extremely rare, representing 3.0% of US childhood and adolescent epithelial tumor cases and 
2.4% of MA cases (n=8). 
   
Melanoma is a carcinoma that almost always develops in the skin, with rare cases developing 
in the eye or mouth.  It is caused by changes in cells called melanocytes, which produce a skin 
pigment called melanin.
13
  There were 107 cases reported from 2000-2009, representing 32.1% 
of Massachusetts epithelial tumors, compared with 33.1% of US cases.  The incidence rates 
increased non-significantly in Massachusetts (APC=4.3%) and decreased significantly in the 
US (APC=-3.7%) (Figure 27).  The majority of melanoma cases occurred in the 15-19 age-
group (77.6%) and the 10-14 age-group (17.8%).  There was no significant difference in the 
percentage of male and female cases (42.1% vs. 57.9%). 
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Figure 26: Age-Adjusted Thyroid Cancer Incidence Rates Among Children and 
Adolescents MA and US SEER, 2000-2009 
Thyroid MA Thyroid SEER
  32 
 
Sources: Massachusetts Cancer Registry and SEER 18 Registries. * Rates are age-adjusted to the US standard 
2000 population for ages 0-19. 
 
Skin carcinoma is a carcinoma of the skin that is not histologically a melanoma nor basal or 
squamous cell carcinomas.  These cases represented less than 1% of US epithelial carcinomas 
and MA carcinomas among children and adolescents (n < 5). 
 
Other/unspecified carcinomas are carcinomas from other sites or an unknown site.  They 
accounted for 22.7% of US and 20.7% of MA epithelial tumors (n=69). 
 
 
Malignant Epithelial Tumor Mortality and Survival: 
 
There were fewer than 5 melanoma deaths and no thyroid cancer deaths among Massachusetts 
children and adolescents from 2000 to 2009.   In addition to these, there were a total of 12 
deaths related to the oral cavity, digestive tract, or respiratory tract organs.  As a result of the 
small incidence numbers for the other epithelial cancers from 2000 to 2004, only melanoma 
and thyroid cancer cause-specific survival analyses were done for Massachusetts cases. 
 
Childhood Cancer MA 5-Year Survival US SEER 5-Year Survival 
Thyroid Cancer (n=53) 100% 99.4% 
Melanoma (n=49) 93.8% 96.3% 
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Figure 27: Age-Adjusted Melanoma Incidence Rates Among Children and 
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SOFT TISSUE SARCOMAS 
 
Soft tissue sarcomas are cancers that develop in the supporting tissues such as muscle, fat, and 
blood vessels.  From 2000-2009, this cancer accounted for 7.1% of MA childhood and 
adolescent cancer cases (n=212) and 7.3% of US cases.   During this period, the incidence rate 
increased non-significantly in Massachusetts (APC= 0.9%) and in the US SEER Registries 
(APC=0.4%) (Figure 28). 
 
 
Sources: Massachusetts Cancer Registry and SEER 18 Registries. * Rates are age-adjusted to the US standard 
2000 population for ages 0-19. 
 
 
There are 4 types of soft tissue sarcomas in children and adolescents.  There were too few cases 
of any of these subtypes to do any trend analysis. 
 
Rhabdomyosarcoma is an aggressive soft tissue tumor that can arise anywhere in the body.
14
  
There were 73 cases diagnosed from 2000-2009. Rhabdomyosarcoma was most commonly 
diagnosed in the youngest and oldest age groups, with 42.5% of the cases diagnosed before the 
age of five and 24.7% diagnosed between 15 and 19 years.  A significantly larger number of 
these cases were male compared to female (61.6% vs. 38.4%).  This subtype accounted for 
34.4% of soft tissue cancers diagnosed among children and adolescents in Massachusetts 
compared with 39.2% diagnosed in the US SEER Registries. 
 
Fibrosarcoma is a malignant tumor that originates in the connective tissue found at the ends of 
bones of the arms or legs and spreads to other surrounding tissue.  There are two types of this 
cancer – infantile, which affects children under the age of one and adult, which can occur in 
older children and adolescents.
15
 There were 21 cases diagnosed from 2000-2009, accounting 
for 9.9% of Massachusetts childhood and adolescent soft issue sarcomas.  In the US SEER 
Registries, fibrosarcoma cases accounted for 11.3% of soft tissue sarcomas.  Fibrosarcoma was 
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Figure 28: Age-Adjusted Soft Tissue Sarcoma Incidence Rates Among 
Children and Adolescents in MA and US SEER, 2000-2009 
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most commonly diagnosed in the 15-19 age group, accounting for 61.9% of all child and 
adolescent fibrosarcoma cases.  
 
Kaposi’s sarcoma (KS) is a cancer that develops from the cells that line lymph or blood 
vessels. The abnormal cells of KS form purple, red, or brown blotches or tumors on the skin.
16
 
This cancer represented less than 1% of US SEER and Massachusetts soft tissue cases (n <5). 
 
Other soft tissue sarcomas includes sarcomas arising from other or unknown sites and 
accounted for 55.2% of soft tissue cancers diagnosed in Massachusetts (n=117) and 40.5% 
diagnosed in the US from 2000-2009.  They were most commonly diagnosed in the older age 
groups, with 18.0%, 20.5%, and 53.0% reported in the 5-9, 10-14, and 15-19 age groups, 
respectively.   
 
 
Soft Tissue Sarcoma Mortality: 
 
In Massachusetts, there were 30 soft tissue sarcoma deaths from 2000-2009.  The five year 
cause-specific cumulative survival percentages for rhabdomyosarcoma and other soft tissue 
sarcomas diagnosed from 2000 to 2004 were compared with US SEER survival percentages. 
 
 
Childhood Cancer MA 5-Year Survival US SEER 5-Year Survival 
Rhabdomyosarcoma (n=35) 68.4% 63.0% 
Other Soft Tissue Sarcoma (n=63)  88.8% 78.9% 
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GERM CELL TUMORS 
 
Germ cell (egg or sperm), trophoblastic (cells outside an early embryo), and other gonadal 
(ovarian or testicular) neoplasms arise from the body’s reproductive cells.4  Among children 
and adolescents in Massachusetts, 66.2% of germ cell tumors were diagnosed after the age of 
14.  From 2000-2009, this cancer accounted for 5.8% of Massachusetts childhood and 
adolescent cancer cases (n=174) and 6.9% of US cases.  Figure 29 compares age-adjusted 
incidence trends from 2000 to 2009 for Massachusetts (APC=2.8%, non-significant) and the 
US (APC=0.7%, non-significant). 
 
 
Sources: Massachusetts Cancer Registry and SEER 18 Registries. * Rates are age-adjusted to the US standard 
2000 population for ages 0-19  
 
There are five types of germ cell tumors in children and adolescents.  There were too few cases 
a year to perform any trend analysis. 
 
Intracranial germ tumor – These are tumors of the brain that develop when the sex cells 
normally found in the ovaries and testes do not migrate down and become trapped in the brain.  
They are most frequently found around the pituitary and pineal glands.
16
 They accounted for 
12.6% of germ cell tumors diagnosed in Massachusetts from 2000-2009 (n=22) and 15.9% 
diagnosed in the US.    
    
Extracranial/Gonadal germ cell – These are germ cell tumors located in neither the brain or 
the testes or ovaries.
15 
They accounted for 13.2% of germ cell tumors diagnosed in 
Massachusetts from 2000-2009 (n=23) and 14.1% diagnosed in the US.   
 
Gonadal germ cell – These are germ cells located in either the testes or ovaries.15  They 
accounted for 64.4% of germ cell tumors diagnosed in Massachusetts from 2000-2009 (n=112) 
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Figure 29: Age-Adjusted Germ Cell Tumor Incidence Rates Among Children 
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and 65.0% of those diagnosed in the US.  In Massachusetts, a significantly larger number of 
these cases were male compared to female (75.0% vs. 25.0%). 
 
Gonadal carcinomas accounted for 5.2% of Massachusetts germ cell tumor cases (n=9) and 
3.4% of US cases. 
 
Other gonadal tumors accounted for 4.6% of germ cell tumor cases (n=8) and 1.6% of US 
cases. 
 
Germ Cell Tumor Mortality and Survival: 
 
Since there were fewer than 10 cases of extracranial/gonadal germ cell tumors diagnosed from 
2000 to 2004, cause-specific survival related analyses were performed for only gonadal germ 
cell tumors in Massachusetts. 
 
Childhood Cancer MA 5-Year Survival US SEER 5-Year Survival 
Gonadal Germ Cell Tumor (n=55) 98.2% 78.9% 
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MALIGNANT BONE TUMORS 
 
Cancers that originate in the bones are known as primary bone cancers.  They occur most often 
in older children and adolescents but can develop at any age.
19
  From 2000-2009, this cancer 
accounted for 4.1% of Massachusetts childhood and adolescent cancer cases (n=124) and 5.3% 
of US SEER cases.   Figure 30 compares age-adjusted incidence trends from 2000 to 2009 for 
Massachusetts (APC=-2.6%, non-significant) and the US (APC=1.2%, non-significant). 
 
 
Sources: Massachusetts Cancer Registry and SEER 18 Registries. * Rates are age-adjusted to the US standard 
2000 population for ages 0-19. 
 
There are four types of bone cancers seen among children and adolescents.  There were too few 
cases to perform any trend analysis on the specific types. 
 
Osteosarcoma is the most common type of bone cancer that develops in areas where the bone 
is growing quickly, such as near the ends of long bones.  Although osteosarcoma can develop 
in any bone, the most common sites are the bones around the knee and the shoulder.
20
  It 
accounted for 58.1% of childhood and adolescent bone cancers diagnosed in Massachusetts 
from 2000-2009 (n=72) and 58.4% of US SEER cases.  Osteosarcoma was most commonly 
diagnosed in the 10-14 (44.4% of cases) and the 15-19 (37.5%) age-groups.  There was no 
significant difference between male and female osteosarcoma cases (55.6% vs. 44.4%). 
 
Chondrosarcoma is a rare bone tumor that accounted for 4.0% of US SEER childhood and 
adolescent bone cancers and 1.6% of 2000-2009 Massachusetts bone cancers (n < 5). 
 
Ewing sarcoma is another type of bone cancer different from osteosarcomas at the 
microscopic tissue level.
21
 It accounted for 36.3% of childhood and adolescent bone cancers 
diagnosed in Massachusetts from 2000-2009 (n=45) and 30.8% of US SEER cases.  As with 
osteosarcoma, the 10-14 and 15-19 age groups accounted for the majority of the cases, 44.4% 
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and 31.1%, respectively. There was no significant difference between males and females 
diagnosed (62.2% vs. 37.8%). 
 
Other bone cancers accounted for 4.0% of malignant bone tumors diagnosed in Massachusetts 
from 2000-2009 (n=5) and 4.8% diagnosed in the US SEER Registries. 
 
Malignant Bone Tumor Mortality: 
 
The five-year cumulative cause-specific survival for osteosarcoma cases diagnosed from 2000 
to 2004 were compared for Massachusetts and the US. 
 
 
Childhood Cancer MA 5-Year Survival US SEER 5-Year Survival 
Osteosarcoma (n=33) 63.5% 68.3% 
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RENAL TUMORS 
 
Renal tumors are those cancers that originate in the kidney.  There were 109 renal tumors 
diagnosed among children and adolescents from 2000 to 2009, representing 3.6% of all 
childhood and adolescent cancers in Massachusetts compared with 3.8% for the US SEER 
Registries. Wilms’ tumor is the most common type of renal tumor among children and 
adolescents, accounting for 89.0% of renal tumor cases diagnosed from 2000-2009 (n=97).  
The majority of Wilms’ tumor cases were diagnosed either before the age of five (66.0%) or 
from five to nine years (27.8%).  There was no significant difference between male and female 
renal tumor cases diagnosed from 2000-2009 (48.6% vs. 51.4%).The other types of renal 
tumors, renal carcinoma and other nephroblastoma accounted for the remaining 11%.  Figure 
31 compares age-adjusted incidence trends from 2000 to 2009 for MA (APC=-0.1%, non-
significant) and the US (APC=1.4%, non-significant).  The numbers were too small to do 
further analysis. 
 
 
Sources: Massachusetts Cancer Registry and SEER 18 Registries. * Rates are age-adjusted to the US standard 
2000 population for ages 0-19. 
 
Malignant Renal Tumor Mortality and Survival: 
 
There were 5 malignant renal tumor deaths in Massachusetts from 2000 to 2009.   Of the 53 
Massachusetts cases diagnosed from 2000 to 2004, 92.2% survived at least five years after 
diagnosis compared to 89.7% of US SEER cases.  While there were no available SEER data for 
Wilms’ tumor, 94.1% of the 51 Massachusetts cases diagnosed from 2000 to 2004 survived at 
least five years. 
 
 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Rate  
per  
100,000 
Year of Diagnosis 
Figure 31: Age-Adjusted Renal Tumor Incidence Rates Among Children 
and Adolescents 0-19, MA and US SEER, 2000-2009 
Renal Tumor MA Renal Tumor SEER
  40 
 
 
RETINOBLASTOMA 
 
Retinoblastoma is a cancer of the eye that occurs among very young children.  About 40% of 
cases of retinoblastoma are due to inherited mutations (changes) in a retinoblastoma-related 
gene.  The remaining 60% of cases of retinoblastoma result from sporadic (random) mutations 
in a gene.
17
  There are no subtypes of retinoblastoma.  There were 42 cases diagnosed from 
2000-2009, representing 1.4% of all cancers in children and adolescents compared to 1.9% for 
the US SEER Registries.  Nearly 100% of these cases were diagnosed before the age of five.  
There was no significant difference between males and females diagnosed from 2000-2009 
(40.5% vs. 59.5%). 
 
Retinoblastoma Mortality and Survival: 
 
There were fewer than 5 deaths from 2000 to 2009 due to retinoblastoma.  There were too few 
incident cases in Massachusetts to do any trend or survival analysis.  Of US SEER cases, 
98.0%  survived at least five years. 
 
 
 
HEPATIC (LIVER) TUMORS 
 
Malignant hepatic tumors are cancers that originate in the liver.  The two types of malignant 
hepatic tumors in children and adolescents are hepatoblastomas and hepatic carcinomas.
17
  
There were 33 hepatic tumors diagnosed from 2000 to 2009, representing 1.1% of all cancers in 
children and adolescents compared with 1.3% for the US SEER Registries. Hepatoblastomas 
accounted for 84.6% of those Massachusetts cases (n=28).  Of all hepatic tumors, 78.9% and 
92.9% of hepatoblastomas were diagnosed before the age of 5.  There was no significant 
difference between males and females diagnosed with hepatic tumors (60.7% vs. 39.3%).  
 
Hepatic Tumor Mortality and Survival: 
 
From 2000-2009, there were 7 deaths from liver cancer.  There were too few incident cases in 
Massachusetts to do any trend or survival analysis.  Of US SEER cases, 62.8% survived at least 
five years. 
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DISCUSSION 
 
From 2000 to 2009, 3001 cases of invasive cancer were diagnosed among children and 
adolescent residents of Massachusetts.  In the same period, 359,058 cancer cases were 
diagnosed among the entire Massachusetts population.  While the overall cancer burden among 
children and adolescents (0.8% of all cancers) was disproportionately much lower compared to 
their proportion in the total population (25.3% of the Massachusetts population), specific 
cancers disproportionately affected the 0-19 years age-group compared to cancers in all groups.    
 
 8.4% of all leukemia cases, 11.5% of all Hodgkin lymphoma cases, and 11.3% of all 
CNS cases occurred among children and adolescents, a much larger representation than 
children’s and adolescents’ proportion of all Massachusetts cancer cases (0.8%).   
 Among all Massachusetts cancer cases, 2.7% of male and 2.4% of female cases were 
leukemia. In contrast, 23.6% of childhood and adolescent male cancer cases and 23.3% 
of childhood and adolescent female cases were leukemia. Leukemia rates were highest 
among children aged 0-4. 
 Among all Massachusetts cancer cases, 5.0% of male and 4.2% of female cases were 
lymphomas. In contrast, 18.7% of childhood and adolescent male cancer cases and 
14.2% of childhood and adolescent female cases were lymphomas.   
 Among all Massachusetts cancer cases, 1.4% of male and 1.3% of female cancer cases 
were CNS cancers. In contrast, 19.0% of childhood and adolescent male cases and 
18.3% of childhood and adolescent female cases were CNS cancers.  
  
The incidence rates of three cancers increased significantly among Massachusetts children and 
adolescents from 2000 to 2009.  
  
The incidence rate of leukemia among Massachusetts children and adolescents increased 
significantly from 2000 to 2009, driven primarily by a significant increase in the incidence of 
acute lymphocytic leukemia (ALL).  This significant trend was not found among either white 
non-Hispanics or Hispanics, the two racial/ethnic groups with a sufficient number of cases to 
perform a trend analysis.  The leukemia increases, while significant, are still relatively small 
(leukemia increased from 2.8/100,000 to 3.5/100,000 over the ten years and acute lymphocytic 
leukemia increased from 3.7 to 4.3/100.000).   The significant increase in Massachusetts rates 
of acute lymphocytic leukemia is consistent with significantly increasing rates at the national 
level.  The American Cancer Society’s publication on childhood leukemia notes the few known 
genetic and environmental factors associated with leukemia, emphasizing the fact that that most 
adults and children with leukemia have no known risk factors.  Lifestyle factors usually take 
many years to influence cancer risk and are usually not related to childhood and adolescent 
cancers.
4
 
 
The incidence rates for lymphoma and Hodgkin lymphoma remained steady from 2000 to 
2009, however, the incidence rate for non-Hodgkin lymphoma (NHL) increased significantly.  
While the overall trend for NHL was significant, examination of the trend line indicated a 
decrease in the rate until 2003 (1.2 to 0.6/100,000), followed by an increase from 2003 to 2007 
(0.6 to 1.6/100,000), followed by a relative steadying of the trend in 2008 and 2009.  The 2009 
rate (1.4 per 100,000) is similar to the 2000 rate (1.2 per 100,000).  National trends which rely 
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on larger numbers and more statistical power showed no significant trend in either direction 
from 2000 to 2009. 
 
Thyroid cancer has been increasing at a significant rate  primarily among adolescents ages 15 
to 19.  As noted earlier, , this increase is consistent with the trend among the adult population in 
Massachusetts.  While other risk factors may also be present, better detection of smaller tumors 
most likely has played a major role in this increase.
12
 
 
In both Massachusetts and the US, mortality rates for all childhood and adolescent cancers 
decreased at a non-significant rate  from 2000 to 2009, remaining around 2.5/100,000.  Due to 
the limited number of deaths in Massachusetts, this report was able to compare mortality trends 
in Massachusetts with those of the US for only leukemia and CNS cancers.  While the trends 
for leukemia decreased non-significantly in Massachusetts and significantly in the US, the 
trends remained stable for CNS cancers.    
 
 Massachusetts cause-specific five-year survival rates were comparable to and sometimes better 
than national percentages released by SEER.  The higher survival rates in Massachusetts may 
be due in part to the higher number of cancer treatment facilities in the Commonwealth.  
Important to note is that the survival figures in this report are based on cancer types as a whole 
and do not control for  co-morbidities, histological subtype, or the  grade of cancer.  A 
limitation of using cause-specific data is the inconsistent attribution of cancer as a cause of 
death when relying on death certificates and the exclusion of other causes of death possibly 
related to the cancer treatment.
 
The American Cancer Society stresses that survival rates are 
‘based on previous outcomes of large numbers of children who had the disease, but they cannot 
predict what will happen in any particular child’s case’.5  The heterogeneity and low incidence 
of childhood cancers greatly complicates attempts to determine causes for specific childhood 
cancers
22
 .The survival times in this report should be interpreted as an overall assessment of 
past survival and not a specific predictor of individual survival.  The decreased mortality rate of 
childhood cancer has been one of the major success stories of medicine in the last 30 years. 
2
  Advances in treatment have contributed to the national five-year survival rates for all 
childhood cancers improving from 58.1% in 1975-1977 to 79.6% in 1996-2003 
23
 with survival 
rates for leukemias, Hodgkin disease, and sarcomas achieving notable improvements.   Despite 
such progress, the Commonwealth must recommit to better understanding the causes of these 
childhood cancers, and provide improved treatments for those children and adolescents who 
face cancer at such a young age.
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Appendix I 
International Classification of Childhood Cancer, Third Edition (ICCC-3)  
Based on ICD-O-3
*
 
 ICD-O-2/ICD-O-3
**
 codes 
Site Group  ICD-O-3 Histology (Type) ICD-O-2/3 Site 
I. Leukemias, myeloproliferative 
diseases, and myelodysplastic 
diseases 
  
 a. Lymphoid leukemias 9820, 9823, 9826, 9827, 9831-
9837, 9940, 9948  
C000-C809 
 b. Acute myeloid leukemias 9840, 9861, 9866, 9867, 9870-
9874, 9891, 9895-9897, 9910, 
9920, 9931 
C000-C809 
 c. Chronic myeloproliferative 
diseases 
9863, 9875, 9876, 9950, 9960-
9964 
C000-C809 
 d. Myelodysplastic syndrome and 
other myeloproliferative diseases 
9945, 9946, 9975, 9980, 9982-
9987, 9989 
C000-C809 
 e. Unspecified and other specified 
leukemias  
9800, 9801, 9805, 9860, 9930 C000-C809 
II. Lymphomas and 
reticuloendothelial neoplasms 
  
 a. Hodgkin lymphomas 9650-9655, 9659, 9661-9665, 
9667 
C000-C809 
 b. Non-Hodgkin lymphomas (except 
Burkitt lymphoma) 
9591, 9670, 9671, 9673, 9675, 
9678-9680, 9684, 9689-9691,  
9695, 9698-9702, 9705, 9708, 
9709, 9714, 9716-9719, 9727-
9729, 9731-9734, 9760-9762, 
9764-9769, 9970 
C000-C809 
 c. Burkitt lymphoma 9687 C000-C809 
 d. Miscellaneous lymphoreticular 
neoplasms 
9740-9742, 9750, 9754-9758 C000-C809 
 e. Unspecified lymphomas 9590, 9596 C000-C809 
III. Central nervous system and 
miscellaneous intracranial and 
intraspinal neoplasms 
  
 a. Ependymomas and choroid 
plexus tumor 
9383, 9390-9394 C000-C809 
 b. Astrocytomas 9380 C72.3 
 9384, 9400-9441, 9420, 9421-
9424, 9440-9442 
C000-C809 
                                                 
*
 Chart from: Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood 
Cancer, 3
rd
 Edition. Cancer 2005;103:1457-67. 
**
 International Classification of Diseases for Oncology, 2
nd/3rd Ed.  
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 c. Intracranial and intraspinal 
embryonal tumors 
9470-9474, 9480, 9508 C000-C809 
 9501-9504 C700-C729 
 d. Other gliomas 9380 
 
C700-C722, C724-
C729, C751, C753 
 9381, 9382, 9430, 9444, 9450, 
9451, 9460 
C000-C809 
 e. Other specified intracranial and 
intraspinal neoplasms 
8270-8281, 8300, 9350-9352,  
9360-9362, 9412, 9413, 9492,  
9493, 9505-9507, 9530-9539, 
9582 
C000-C809 
 f. Unspecified intracranial and 
intraspinal neoplasms 
8000-8005 C700-C729, C751-
C753 
IV. Neuroblastoma and other 
peripheral nervous cell tumors 
  
 a. Neuroblastoma and 
ganglioneuroblastoma 
9490, 9500 C000-C809 
 
 b. Other peripheral nervous cell 
tumors 
8680-8683, 8690-8693, 8700, 
9520-9523 
C000-C809 
 9501-9504 C000-C699, C739-
C768, C809 
V. Retinoblastoma 9510-9514 C000-C809 
VI. Renal Tumors   
 a. Nephroblastoma and other non-
epithelial renal tumors 
8959, 8964-8967 
 
C000-C809 
 
 8963, 9364 C649 
         b. Wilm’s Tumor 8960 C000-C809 
 c. Renal carcinomas 8010-8041, 8050-8075, 8082, 
8120-8122, 8130-8141, 8143, 
8155, 8190-8201, 8210, 8211, 
8221-8231, 8240, 8241, 8244-
8246, 8260-8263, 8290, 8310, 
8320, 8323, 8401, 8430, 8440, 
8480-8490, 8504, 8510, 8550, 
8560-8576 
C649 
 8311, 8312, 8316-8319, 8361 C000-C809 
 d. Unspecified malignant renal 
tumors 
8000-8005 C649 
VII. Hepatic Tumors   
 a. Hepatoblastoma 8970 C000-C809 
 b. Hepatic carcinomas 8010-8041, 8050-8075, 8082, 
8120-8122, 8140, 8141, 8143, 
8155, 8190-8201, 8210, 8211, 
8230, 8231, 8240, 8241, 8244-
8246, 8260-8264, 8310, 8320, 
8323, 8401, 8430, 8440, 8480-
C220, C221 
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8490, 8504, 8510, 8550, 8560-
8576 
 8160-8180 C000-C809 
 c. Unspecified malignant hepatic 
tumors 
8000-8005 C220, C221 
VIII. Malignant Bone Tumors   
 a. Osteosarcomas 9180-9187, 9191-9195, 9200 C400-C419, C760-
C768, C809 
 b. Chondrosarcomas 9210, 9220, 9240 C400-C419, C760-
C768, C809 
 9221, 9230, 9241-9243 C000-C809 
 c. Ewing’s tumors and related 
sarcomas of the bone 
9260 C400-C419,  
C760-C768, C80.9 
 9363-9365 C400-C419 
 d. Other specified malignant bone 
tumors 
8810, 8811, 8823, 8830  C400-C419 
 8812, 9250, 9261, 9262, 9270-
9275, 9280-9282, 9290, 9330-
9302, 9310-9312, 9320-9322, 
9330, 9340-9342, 9370-9372 
C000-C809 
 e. Unspecified malignant bone 
tumors 
8000-8005, 8800, 8801, 8803-
8805 
C400-C419 
 
IX. Soft tissue and other extraosseous 
sarcomas 
  
 a. Rhabdomyosarcomas 8900-8905, 8910, 8912, 8920, 
8991 
C000-C809 
 b. Fibrosarcomas, peripheral nerve 
sheath tumors, and other fibrous 
neoplasms 
8810, 8811, 8813-8815, 8821, 
8823, 8834-8835  
C000-C399, C440-
C768, C809 
 8820, 8822, 8824-8827, 9150,  
9160, 9491, 9540-9571, 9580 
C000-C809 
 c. Kaposi sarcoma 9140 C000-C809 
 d. Other specified soft-tissue 
sarcomas 
8587, 8710-8713, 8806, 8831-
8833, 8836, 8840-8842, 8850-
8858, 8860-8862, 8870, 8880, 
8881, 8890-8898, 8921, 8982, 
8990, 9040-9044, 9120-9125,  
9130-9133, 9135, 9136, 9141, 
9142, 9161, 9170-9175, 9231, 
9251, 9252, 9373, 9581 
C000-C809 
 8830 C000-C399, 
C440-C768, C809 
 8963 C000-C639, 
C659-C699, C739-
C768, C809 
 9180, 9210, 9220, 9240 C490-C499,  
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 9260 C000-C399, C470-
C759 
 9364 C000-C399, 
C470-C639, 
C659-C699, 
C739-C768, 
C809 
 9365 C000-C399, 
C470-C639, 
C659-C768, 
C809 
 e. Unspecified soft-tissue sarcomas 8800-8805 C000-C399, C440-
C768, 
C809 
X. Germ cell tumors, trophoblastic 
tumors, and neoplasms of gonads  
  
 a. Intracranial and intraspinal germ 
cell tumors 
9060-9065, 9070-9072, 9080-
9085, 9100, 9101 
C700-C729, C751-
C753 
 b. Malignant extracranial and 
extragonadal germ cell tumors 
9060-9065, 9070-9072, 9080-
9085, 9100-9105 
C000-C559, C570-
C619, C630-C699, 
C739-C750, C754-
C768, C809 
 c. Malignant gonadal germ cell 
tumors 
9060-9065, 9070-9073, 9080-
9085, 9090, 9091, 9100, 9101 
C569, C620-C629 
 d. Gonadal carcinomas 8010-8041, 8050-8075, 8082, 
8120-8122, 8130-8141, 8143, 
8190-8201, 8210, 8211, 8221-
8241, 8244-8246, 8260-8263, 
8290, 8310, 8313, 8320, 8323, 
8380-8384, 8430, 8440, 8480-
8490, 8504, 8510, 8550, 8560-
8573, 9000, 9014, 9015 
C569, C620-C629 
 8441-8444, 8450, 8451, 8460-
8473 
C000-C809 
 e. Other and unspecified malignant 
gonadal tumors 
8590-8671 C000-C809 
 8000-8005 C569, C620-C629 
XI. Other malignant epithelial 
neoplasms and malignant 
melanomas 
  
 a. Adrenocortical carcinomas 8370-8375 C000-C809 
 b. Thyroid carcinomas 8010-8041, 8050-8075, 8082, 
8120-8122, 8130-8141, 8190, 
8200, 8201, 8211, 8230, 8231, 
8244-8246, 8260-8263, 8290, 
8310, 8320, 8323, 8430, 8440, 
C739 
  47 
8480, 8481, 8510, 8560-8573 
 8330-8337, 8340-8347, 8350 C000-C809 
 c. Nasopharyngeal carcinomas 8010-8041, 8050-8075, 8082,   
8083, 8120-8122, 8130-8141, 
8190, 8200, 8201, 8211, 8230, 
8231, 8244-8246, 8260-8263, 
8290, 8310, 8320, 8323, 8430, 
8440, 8480, 8481, 8550-8576 
C110-C119 
 d. Malignant melanomas 8720-8780, 8790 C000-C809 
 e. Skin carcinomas 8010-8041, 8050-8075, 8078, 
8082, 8090-8110, 8140, 8143, 
8147, 8190, 8200, 8240, 8246, 
8247, 8260, 8310, 8320, 8323, 
8390-8420, 8430, 8480, 8542, 
8560, 8570-8573, 8940, 8941 
C440-C449 
 f. Other and unspecified carcinomas 8010-8084, 8120-8157, 8190-
8264, 8290, 8310, 8313-8315,  
8320-8325, 8360, 8380-8384, 
8430-8440, 8452-8454, 8480-
8586, 8588-8589, 8940, 8941, 
8983, 9000, 9010-9016, 9020, 
9030 
C000-C109, C129-
C218, C239-C399, 
C480-C488, C500-
C559, C570-C619, 
C630-C639, C659-
C729, C750-C768, 
C809 
XII. Other and unspecified malignant 
neoplasms 
  
 a. Other specified malignant tumors 8930-8936, 8950, 8951, 8971-
8981, 9050-9055, 9110 
C000-C809 
 9363 C000-C399, C470-
C759 
 b. Other unspecified malignant 
tumors 
8000-8005 C000-C218, C239-
C399, C420-C559, 
C570-C619, C630-
C639, C659-C699, 
C739-C750, C754-
C809 
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Appendix II 
ICD-9 
*
 and ICD-10* Codes 
 
 
Cancer site/type 
 
 
ICD-9 code 
 
ICD-10 code 
 
Bone 
 
 
170 
 
C40-C41 
 
Brain & Central Nervous System 
 
 
191-192 
 
C70-C72 
 
Kidney 
 
 
189.0-189.1 
 
C64-C65 
 
Leukemia 
 
 
204-208 
 
C91-C95 
 
Liver 
 
 
155 
 
C22.0, C22.2-C22.4, 
C22.7, C22.9 
 
 
Lymphoma 
 
 
200, 201, 202.0-202.2, 
202.8-202.9 
 
 
C81, C82-C85, C96.3 
 
Melanoma/Skin 
 
 
172-173 
 
C43, C44, C46+ 
 
Thyroid 
 
 
193 
 
C73 
 
 
 
                                                 
* International Classification of Diseases, Ninth Revision, Clinical Modification  
* International Classification of Diseases, Tenth Revision, Clinical Modification 
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Appendix III: Childhood and Adolescent Cancer Counts, 2000-2009 
All Cancers: Male Female    
2000 157 136    
2001 137 134    
2002 149 123    
2003 140 155    
2004 173 122    
2005 158 142    
2006 185 165    
2007 162 133    
2008 154 153    
2009 188 135    
2000-2009 1603 1398    
      
All Cancers: 0-4 5-9 10-14 15-19  
2000 91 50 58 94  
2001 88 45 56 82  
2002 68 54 57 93  
2003 99 55 50 91  
2004 100 43 58 94  
2005 84 36 64 116  
2006 108 60 62 120  
2007 83 52 60 100  
2008 92 46 52 117  
2009 101 49 48 125  
2000-2009 914 490 565 1032  
      
All Cancers: White, NH Black, NH Asian, NH Hispanic  
2000 237 21 9 17  
2001 220 18 7 20  
2002 225 16 7 21  
2003 243 14 5 28  
2004 236 14 5 32  
2005 240 15 18 20  
2006 279 19 13 34  
2007 229 17 13 29  
2008 239 18 8 37  
2009 239 23 23 34  
2000-2009 2387 175 108 272  
      
Leukemia: Total ALL AML   
2000 62 46 13   
2001 59 45 8   
2002 73 53 14   
2003 68 55 9   
2004 74 54 15   
2005 73 60 11   
2006 76 58 10   
2007 69 54 12   
2008 82 66 14   
2009 69 57 9   
2000-2009 705 548 115   
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Lymphoma: Total HL NHL   
2000 50 27 20   
2001 43 23 14   
2002 37 18 14   
2003 44 29 9   
2004 45 25 16   
2005 61 32 18   
2006 64 34 19   
2007 49 17 27   
2008 49 21 22   
2009 57 26 23   
2000-2009 499 252 182   
      
CNS: Total Astrocytoma Embryonal    
2000 59 29 13   
2001 60 31 13   
2002 45 22 8   
2003 55 33 10   
2004 67 33 15   
2005 55 30 9   
2006 61 30 11   
2007 55 29 9   
2008 49 19 14   
2009 57 24 9   
2000-2009 563 280 111   
      
Peripheral NC: Total Neuroblastoma    
2000 23 23    
2001 23 22    
2002 20 20    
2003 19 19    
2004 15 15    
2005 9 8    
2006 20 20    
2007 27 27    
2008 19 19    
2009 20 20    
2000-2009 195 193    
      
Renal Tumors:  Bone Tumors:  Soft Tissue:  
2000 14 2000 15 2000 22 
2001 10 2001 8 2001 21 
2002 10 2002 11 2002 19 
2003 16 2003 15 2003 30 
2004 8 2004 9 2004 16 
2005 6 2005 16 2005 20 
2006 8 2006 22 2006 23 
2007 5 2007 11 2007 24 
2008 13 2008 8 2008 21 
2009 19 2009 9 2009 16 
2000-2009 109 2000-2009 124 2000-2009 212 
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Germ Cell Tumor:      
2000 15     
2001 13     
2002 22     
2003 12     
2004 20     
2005 12     
2006 19     
2007 13     
2008 22     
2009 26     
2000-2009 174     
      
Epithelial Tumor: Total Melanoma Thyroid    
2000 25 7 9   
2001 26 8 10   
2002 33 12 15   
2003 28 10 8   
2004 31 13 12   
2005 35 8 21   
2006 42 12 17   
2007 37 14 14   
2008 38 10 24   
2009 38 13 16   
2000-2009 333 107 146   
      
2000-2009 Cases: Male Female    
Leukemia 379 326    
Lymphoma 300 199    
CNS 304 256    
PNC 107 88    
Retinoblastoma 17 25    
Renal Tumors 53 56    
Hepatic Tumors 18 15    
Bone Tumors 72 52    
Soft Tissue 119 93    
Germ Cell 108 66    
Epithelial Tumor 120 213    
Other 6 9    
All Cancers 1603 1398    
2000-2009 Cases: 0-4 5-9 10-14 15-19  
Leukemia 330 131 115 129  
Lymphoma 26 62 141 270  
CNS 180 162 111 107  
PNC 158 22 10 5  
Retinoblastoma 41 0 <5 0  
Renal Tumors 68 30 7 <5  
Hepatic Tumors 26 <5 <5 <5  
Bone Tumors 5 20 55 44  
Soft Tissue 46 38 35 93  
Germ Cell 27 12 20 115  
Epithelial Tumor <5 10 66 256  
Other 6 <5 <5 6  
 914 490 565 1032  
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2000-2009 Cases: White, NH Black, NH Asian, NH Hispanic Other/Unknown 
Leukemia 551 33 31 82 8 
Lymphoma 398 35 19 43 <5 
CNS 463 23 19 46 9 
PNC 162 10 6 15 <5 
Retinoblastoma 30 <5 0 5 <5 
Renal Tumors 89 12 <5 6 <5 
Hepatic Tumors 19 <5 <5 7 0 
Bone Tumors 99 10 5 9 <5 
Soft Tissue 155 23 8 21 5 
Germ Cell 146 5 7 12 <5 
Epithelial Tumor 265 14 7 25 22 
Other 10 <5 <5 <5 0 
 2387 175 108 272 59 
Cancer Deaths: Total Leukemia CNS   
2000 49 15 15   
2001 38 7 7   
2002 37 8 9   
2003 43 13 8   
2004 36 11 8   
2005 36 10 6   
2006 33 10 8   
2007 40 13 11   
2008 42 11 9   
2009 32 9 10   
2000-2009 386 107 91   
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